Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

175.86 +1.14 (+0.65%)
Streaming Delayed Price Updated: 11:18 AM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Earnings Scheduled For January 22, 2025
 
Via Benzinga
Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
The CNN Business Fear & Greed Index measures market sentiment, with higher fear putting pressure on stocks. 
Via Benzinga
Topics Government Stocks
Looking Into Johnson & Johnson's Recent Short Interest
 
Via Benzinga
Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday
 
Via Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Big Trading Day Ends With Q4 Earnings Beats: NFLX, UAL, COF
Markets had a strong session on the first full day of President Trump’s second administration. Indexes have rocketed up from 2025 lows hit a week to a week and a half ago. 
Via Talk Markets
Topics Government Stocks / Equities
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside 
Via Benzinga
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the key items and numbers to watch. 
Via Benzinga
Topics Stocks
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally 
Via MarketBeat
Topics Economy Energy
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
This magnificent company has been paying a continuous dividend to its shareholders since 1816. 
Via The Motley Fool
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive 
Via MarketBeat
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors. 
Via The Motley Fool
10 One Decision Stocks To Buy Now
The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats. 
Via Talk Markets
Topics Stocks / Equities
Got $200? 2 Dividend Stocks to Buy and Hold Forever
These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock. 
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts and biotech recovery delays. 
Via Benzinga
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.